Review





Similar Products

97
ATCC sw1990 cell lines
Sw1990 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sw1990 cell lines/product/ATCC
Average 97 stars, based on 1 article reviews
sw1990 cell lines - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

97
ATCC pancreatic carcinoma cell lines sw1990
Transwell assay was used for assessment of anti-invasive potential of the Ph-triazole against <t>SW1990</t> and PANC-1 cells in vitro after incubation with 0.5, 8, and 32 µM concentrations. Quantification of the invaded cells was performed, and pictures were taken at x100 magnification. ** p < 0.01 and * p < 0.05 relative to control cells.
Pancreatic Carcinoma Cell Lines Sw1990, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pancreatic carcinoma cell lines sw1990/product/ATCC
Average 97 stars, based on 1 article reviews
pancreatic carcinoma cell lines sw1990 - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

97
ATCC pancreatic cancer cell lines sw1990
Transwell assay was used for assessment of anti-invasive potential of the Ph-triazole against <t>SW1990</t> and PANC-1 cells in vitro after incubation with 0.5, 8, and 32 µM concentrations. Quantification of the invaded cells was performed, and pictures were taken at x100 magnification. ** p < 0.01 and * p < 0.05 relative to control cells.
Pancreatic Cancer Cell Lines Sw1990, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pancreatic cancer cell lines sw1990/product/ATCC
Average 97 stars, based on 1 article reviews
pancreatic cancer cell lines sw1990 - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

97
ATCC human tumor cell lines sw1990
Antibiotics screening identifies ciprofloxacin (CFX) synergies with RSL3 to inhibit PDAC cell viability. A, PANC1 cells were treated with 50 antibiotics (20, 30, 40, and 50 μg/ml) in combination with RSL3 (0.25, 0.5, 0.75, and 1 μM) at four concentration gradients for 24 h. Cell viability was measured by CCK-8 assay. Synergy score for drug combinations quantified by zero interaction potency (ZIP) model in SynergyFinder web application (version 3.0). Synergy score less than −10 means antagonistic, from −10 to 10 means additive, and larger than 10 means synergistic. B, heatmap representing ZIP synergy score of the 50 antibiotics in combination with RSL3 for treatment of PANC1 cells. Data were representative of independent experiments. C, cell viability curves of PANC1, <t>SW1990,</t> HeLa, and OVCAR-3 cells treated with different concentrations of CFX in combination with RSL3 for 24 h. D, ZIP synergy scores of CFX in combination with RSL3 in PANC1, SW1990, HeLa, and OVCAR-3 cells. E, clone formation image of PANC1, SW1990, and HeLa cells untreated (Ctrl group) or treated with RSL3 (0.5 μM) in the presence or absence of CFX (50 μg/ml) for 24 h, and cell clone formation was detected after 2 weeks. Data are presented as the mean ± SD from at least three independent experiments. p Values were calculated using two-way ANOVA ( C ) or one-way ANOVA ( E ). CCK-8, Cell Counting Kit-8; PDAC, pancreatic ductal adenocarcinoma.
Human Tumor Cell Lines Sw1990, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human tumor cell lines sw1990/product/ATCC
Average 97 stars, based on 1 article reviews
human tumor cell lines sw1990 - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

97
ATCC human pancreatic ductal carcinoma cell lines sw1990
Antibiotics screening identifies ciprofloxacin (CFX) synergies with RSL3 to inhibit PDAC cell viability. A, PANC1 cells were treated with 50 antibiotics (20, 30, 40, and 50 μg/ml) in combination with RSL3 (0.25, 0.5, 0.75, and 1 μM) at four concentration gradients for 24 h. Cell viability was measured by CCK-8 assay. Synergy score for drug combinations quantified by zero interaction potency (ZIP) model in SynergyFinder web application (version 3.0). Synergy score less than −10 means antagonistic, from −10 to 10 means additive, and larger than 10 means synergistic. B, heatmap representing ZIP synergy score of the 50 antibiotics in combination with RSL3 for treatment of PANC1 cells. Data were representative of independent experiments. C, cell viability curves of PANC1, <t>SW1990,</t> HeLa, and OVCAR-3 cells treated with different concentrations of CFX in combination with RSL3 for 24 h. D, ZIP synergy scores of CFX in combination with RSL3 in PANC1, SW1990, HeLa, and OVCAR-3 cells. E, clone formation image of PANC1, SW1990, and HeLa cells untreated (Ctrl group) or treated with RSL3 (0.5 μM) in the presence or absence of CFX (50 μg/ml) for 24 h, and cell clone formation was detected after 2 weeks. Data are presented as the mean ± SD from at least three independent experiments. p Values were calculated using two-way ANOVA ( C ) or one-way ANOVA ( E ). CCK-8, Cell Counting Kit-8; PDAC, pancreatic ductal adenocarcinoma.
Human Pancreatic Ductal Carcinoma Cell Lines Sw1990, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human pancreatic ductal carcinoma cell lines sw1990/product/ATCC
Average 97 stars, based on 1 article reviews
human pancreatic ductal carcinoma cell lines sw1990 - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

97
ATCC human pancreatic cancer cell line sw1990
Antibiotics screening identifies ciprofloxacin (CFX) synergies with RSL3 to inhibit PDAC cell viability. A, PANC1 cells were treated with 50 antibiotics (20, 30, 40, and 50 μg/ml) in combination with RSL3 (0.25, 0.5, 0.75, and 1 μM) at four concentration gradients for 24 h. Cell viability was measured by CCK-8 assay. Synergy score for drug combinations quantified by zero interaction potency (ZIP) model in SynergyFinder web application (version 3.0). Synergy score less than −10 means antagonistic, from −10 to 10 means additive, and larger than 10 means synergistic. B, heatmap representing ZIP synergy score of the 50 antibiotics in combination with RSL3 for treatment of PANC1 cells. Data were representative of independent experiments. C, cell viability curves of PANC1, <t>SW1990,</t> HeLa, and OVCAR-3 cells treated with different concentrations of CFX in combination with RSL3 for 24 h. D, ZIP synergy scores of CFX in combination with RSL3 in PANC1, SW1990, HeLa, and OVCAR-3 cells. E, clone formation image of PANC1, SW1990, and HeLa cells untreated (Ctrl group) or treated with RSL3 (0.5 μM) in the presence or absence of CFX (50 μg/ml) for 24 h, and cell clone formation was detected after 2 weeks. Data are presented as the mean ± SD from at least three independent experiments. p Values were calculated using two-way ANOVA ( C ) or one-way ANOVA ( E ). CCK-8, Cell Counting Kit-8; PDAC, pancreatic ductal adenocarcinoma.
Human Pancreatic Cancer Cell Line Sw1990, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human pancreatic cancer cell line sw1990/product/ATCC
Average 97 stars, based on 1 article reviews
human pancreatic cancer cell line sw1990 - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

Image Search Results


Transwell assay was used for assessment of anti-invasive potential of the Ph-triazole against SW1990 and PANC-1 cells in vitro after incubation with 0.5, 8, and 32 µM concentrations. Quantification of the invaded cells was performed, and pictures were taken at x100 magnification. ** p < 0.01 and * p < 0.05 relative to control cells.

Journal: PLOS One

Article Title: Ph-triazole as a therapeutic agent for pancreatic cancer: Synthesis, in silico, and in vitro evaluation

doi: 10.1371/journal.pone.0334618

Figure Lengend Snippet: Transwell assay was used for assessment of anti-invasive potential of the Ph-triazole against SW1990 and PANC-1 cells in vitro after incubation with 0.5, 8, and 32 µM concentrations. Quantification of the invaded cells was performed, and pictures were taken at x100 magnification. ** p < 0.01 and * p < 0.05 relative to control cells.

Article Snippet: The pancreatic carcinoma cell lines SW1990 and PANC-1 as well as the normal pancreatic duct epithelial cell line (HPDE6-C7) were provided by the American Type Culture Collection (ATCC).

Techniques: Transwell Assay, In Vitro, Incubation, Control

The cells were incubated with 0.5, 8, and 32 µM concentration of Ph-triazole for 72 h in an incubator at 37 °C. Western blotting was performed to assess the expression P53 in SW1990 and PANC-1 cells. ** p < 0.01 and * p < 0.05 relative to control cells.

Journal: PLOS One

Article Title: Ph-triazole as a therapeutic agent for pancreatic cancer: Synthesis, in silico, and in vitro evaluation

doi: 10.1371/journal.pone.0334618

Figure Lengend Snippet: The cells were incubated with 0.5, 8, and 32 µM concentration of Ph-triazole for 72 h in an incubator at 37 °C. Western blotting was performed to assess the expression P53 in SW1990 and PANC-1 cells. ** p < 0.01 and * p < 0.05 relative to control cells.

Article Snippet: The pancreatic carcinoma cell lines SW1990 and PANC-1 as well as the normal pancreatic duct epithelial cell line (HPDE6-C7) were provided by the American Type Culture Collection (ATCC).

Techniques: Incubation, Concentration Assay, Western Blot, Expressing, Control

Antibiotics screening identifies ciprofloxacin (CFX) synergies with RSL3 to inhibit PDAC cell viability. A, PANC1 cells were treated with 50 antibiotics (20, 30, 40, and 50 μg/ml) in combination with RSL3 (0.25, 0.5, 0.75, and 1 μM) at four concentration gradients for 24 h. Cell viability was measured by CCK-8 assay. Synergy score for drug combinations quantified by zero interaction potency (ZIP) model in SynergyFinder web application (version 3.0). Synergy score less than −10 means antagonistic, from −10 to 10 means additive, and larger than 10 means synergistic. B, heatmap representing ZIP synergy score of the 50 antibiotics in combination with RSL3 for treatment of PANC1 cells. Data were representative of independent experiments. C, cell viability curves of PANC1, SW1990, HeLa, and OVCAR-3 cells treated with different concentrations of CFX in combination with RSL3 for 24 h. D, ZIP synergy scores of CFX in combination with RSL3 in PANC1, SW1990, HeLa, and OVCAR-3 cells. E, clone formation image of PANC1, SW1990, and HeLa cells untreated (Ctrl group) or treated with RSL3 (0.5 μM) in the presence or absence of CFX (50 μg/ml) for 24 h, and cell clone formation was detected after 2 weeks. Data are presented as the mean ± SD from at least three independent experiments. p Values were calculated using two-way ANOVA ( C ) or one-way ANOVA ( E ). CCK-8, Cell Counting Kit-8; PDAC, pancreatic ductal adenocarcinoma.

Journal: The Journal of Biological Chemistry

Article Title: Ciprofloxacin enhances RSL3-induced ferroptosis by promoting mitochondrial Zn 2+ accumulation via the STING1–CAV2 pathway

doi: 10.1016/j.jbc.2025.110653

Figure Lengend Snippet: Antibiotics screening identifies ciprofloxacin (CFX) synergies with RSL3 to inhibit PDAC cell viability. A, PANC1 cells were treated with 50 antibiotics (20, 30, 40, and 50 μg/ml) in combination with RSL3 (0.25, 0.5, 0.75, and 1 μM) at four concentration gradients for 24 h. Cell viability was measured by CCK-8 assay. Synergy score for drug combinations quantified by zero interaction potency (ZIP) model in SynergyFinder web application (version 3.0). Synergy score less than −10 means antagonistic, from −10 to 10 means additive, and larger than 10 means synergistic. B, heatmap representing ZIP synergy score of the 50 antibiotics in combination with RSL3 for treatment of PANC1 cells. Data were representative of independent experiments. C, cell viability curves of PANC1, SW1990, HeLa, and OVCAR-3 cells treated with different concentrations of CFX in combination with RSL3 for 24 h. D, ZIP synergy scores of CFX in combination with RSL3 in PANC1, SW1990, HeLa, and OVCAR-3 cells. E, clone formation image of PANC1, SW1990, and HeLa cells untreated (Ctrl group) or treated with RSL3 (0.5 μM) in the presence or absence of CFX (50 μg/ml) for 24 h, and cell clone formation was detected after 2 weeks. Data are presented as the mean ± SD from at least three independent experiments. p Values were calculated using two-way ANOVA ( C ) or one-way ANOVA ( E ). CCK-8, Cell Counting Kit-8; PDAC, pancreatic ductal adenocarcinoma.

Article Snippet: Human tumor cell lines SW1990 (CRL-2172), PANC1 (CRL-1469), HeLa (CCL-2), and OVCAR-3 (HTB-161) were procured from the American Type Culture Collection and examined every 3 months to ensure they remained free of mycoplasma contamination.

Techniques: Concentration Assay, CCK-8 Assay, Cell Counting

Ciprofloxacin (CFX) amplifies RSL3-driven ferroptosis. A, cell viability of PANC1, SW1990, and HeLa cells following treatment with different concentrations of CFX for 24 h. B, cell viability of PANC1, SW1990, and HeLa cells treated with RSL3 in the presence or absence of CFX (50 μg/ml) and liproxstatin-1 (Lip-1, 1 μM) for 24 h. C, representative Hoechst 33342 and propidium iodide (PI) staining images of PANC1, SW1990, and HeLa cells treated with RSL3 (1 μM) in the presence or absence of CFX (50 μg/ml) and Lip-1 (1 μM) for 24 h. Scale bar represents 200 μm. Quantification of PI-positive cells is shown. D, lipid reactive oxygen species (ROS) of PANC1 and SW1990 cells treated with RSL3 (1 μM) in the presence or absence of CFX (50 μg/ml) and ferrostatin-1 (Fer-1, 1 μM) for 12 h. E, malondialdehyde (MDA) of PANC1 and SW1990 cells treated with RSL3 (1 μM) in the presence or absence of CFX (50 μg/ml) for 12 h. F, fluorescence imaging of Phen Green SK (Fe 2+ indicator) in PANC1 and HeLa cells treated with RSL3 (1 μM) in the presence or absence of CFX (50 μg/ml) for 12 h. Scale bar represents 200 μm. The relative fluorescence intensity is shown. G, GSH level of PANC1 cells treated with RSL3 (1 μM) in the presence or absence of CFX (50 μg/ml) for 12 h. H, cell viability of PANC1 and HeLa cells treated with CFX (50 μg/ml) in the presence or absence of RSL3 (1 μM), staurosporine (STS, 1 μM), and TSZ (tumor necrosis factor-α, SM-164, and Z-VAD-FMK) for 24 h. Cell viability of PANC1 and HeLa cells treated with STS (1 μM) and TSZ (TNF-α, SM-164, and Z-VAD-FMK) in the presence or absence of the corresponding inhibitors (Z-VAD-FMK, 20 μM; necrosulfonamide/NSA, 2 μM) for 24 h. Data are presented as the mean ± SD from at least three independent experiments. p Values were calculated using two-way ANOVA ( B ) or one-way ANOVA ( C – H ). ns means no significance.

Journal: The Journal of Biological Chemistry

Article Title: Ciprofloxacin enhances RSL3-induced ferroptosis by promoting mitochondrial Zn 2+ accumulation via the STING1–CAV2 pathway

doi: 10.1016/j.jbc.2025.110653

Figure Lengend Snippet: Ciprofloxacin (CFX) amplifies RSL3-driven ferroptosis. A, cell viability of PANC1, SW1990, and HeLa cells following treatment with different concentrations of CFX for 24 h. B, cell viability of PANC1, SW1990, and HeLa cells treated with RSL3 in the presence or absence of CFX (50 μg/ml) and liproxstatin-1 (Lip-1, 1 μM) for 24 h. C, representative Hoechst 33342 and propidium iodide (PI) staining images of PANC1, SW1990, and HeLa cells treated with RSL3 (1 μM) in the presence or absence of CFX (50 μg/ml) and Lip-1 (1 μM) for 24 h. Scale bar represents 200 μm. Quantification of PI-positive cells is shown. D, lipid reactive oxygen species (ROS) of PANC1 and SW1990 cells treated with RSL3 (1 μM) in the presence or absence of CFX (50 μg/ml) and ferrostatin-1 (Fer-1, 1 μM) for 12 h. E, malondialdehyde (MDA) of PANC1 and SW1990 cells treated with RSL3 (1 μM) in the presence or absence of CFX (50 μg/ml) for 12 h. F, fluorescence imaging of Phen Green SK (Fe 2+ indicator) in PANC1 and HeLa cells treated with RSL3 (1 μM) in the presence or absence of CFX (50 μg/ml) for 12 h. Scale bar represents 200 μm. The relative fluorescence intensity is shown. G, GSH level of PANC1 cells treated with RSL3 (1 μM) in the presence or absence of CFX (50 μg/ml) for 12 h. H, cell viability of PANC1 and HeLa cells treated with CFX (50 μg/ml) in the presence or absence of RSL3 (1 μM), staurosporine (STS, 1 μM), and TSZ (tumor necrosis factor-α, SM-164, and Z-VAD-FMK) for 24 h. Cell viability of PANC1 and HeLa cells treated with STS (1 μM) and TSZ (TNF-α, SM-164, and Z-VAD-FMK) in the presence or absence of the corresponding inhibitors (Z-VAD-FMK, 20 μM; necrosulfonamide/NSA, 2 μM) for 24 h. Data are presented as the mean ± SD from at least three independent experiments. p Values were calculated using two-way ANOVA ( B ) or one-way ANOVA ( C – H ). ns means no significance.

Article Snippet: Human tumor cell lines SW1990 (CRL-2172), PANC1 (CRL-1469), HeLa (CCL-2), and OVCAR-3 (HTB-161) were procured from the American Type Culture Collection and examined every 3 months to ensure they remained free of mycoplasma contamination.

Techniques: Staining, Fluorescence, Imaging